Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6517
    -0.0019 (-0.29%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin AUD

    108,568.14
    +2,319.20 (+2.18%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6034
    +0.0004 (+0.06%)
     
  • AUD/NZD

    1.0905
    +0.0025 (+0.23%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros

Novo Nordisk A/S NVO announced entering into exclusive negotiations with BIO JAG to acquire its controlling stake in BIOCORP, subsequently issuing a tender offer to acquire all remaining outstanding shares in BIOCORP for 35 euro per share in cash, bringing up the total equity value to approximately 154 million euros.

The total equity value, as estimated, represents a premium of 19.5% over BIOCORP’s closing market price on Jun 2, 2023 and 45.2% compared to the volume-weighted average trading prices of the last 90 trading days.

BIO JAG is the majority shareholder in BIOCORP, which is a French company specializing in the design, development and manufacturing of delivery systems and innovative medical devices, including Mallya, a bluetooth-enabled smart add-on device for pen injectors.

In the year so far, shares of Novo Nordisk have gained 16.1% against the industry’s 0.2% decline.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

ADVERTISEMENT

Per the proposed transaction, Novo Nordisk is looking to acquire BIO JAG’s entire stake in BIOCORP, representing 45.30% of its share capital and 62.19% of its theoretical voting rights. Subject to the successful acquisition of BIO JAG’s stake in BIOCORP, NVO will pursue the acquisition of the shares held in BIOCORP by certain minority shareholders, including Nyenburgh, Greenstock and Vatel Capital, representing, in aggregate,19.03% of the share capital and 13.07% of the theoretical voting rights of BIOCORP, at the same price per share.

This acquisition of BIO JAG’s majority stake, along with the subsequent acquisition of BIOCORP’s shares held by the minority shareholders, is together referred to as Block Purchase. NVO will only be able to sign a definitive document with BIO JAG following the information and consultation of BIOCORP’S Works Council. Also, the completion of the Block Purchase will be subject to customary regulatory approvals.

Based on the fruitful relationship between the companies in the past, Novo Nordisk expects to speed up the innovation process for these injections, upon acquisition of BIOCORP, by making use of its robust infrastructure and large-scale manufacturing capabilities. Subject to successful acquisition, the company aims to develop state-of-the-art devices and delivery solutions, which will improve care for people living with serious chronic diseases worldwide.

Novo Nordisk A/S Price and Consensus

Novo Nordisk A/S Price and Consensus
Novo Nordisk A/S Price and Consensus

Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote

Zacks Rank and Other Stocks to Consider

Novo Nordisk currently sports a Zacks Rank #1 (Strong Buy).

A few other top-ranked stocks in the overall medical sector are Novartis NVS, Akero Therapeutics AKRO and Adaptimmune Therapeutics ADAP, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 90 days, the Zacks Consensus Estimate for Novartis’ 2023 earnings per share has increased from $6.52 to $6.67. In the year so far, shares of Novartis have gained by 9%.

NVS beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 5.15%.

In the past 90 days, the Zacks Consensus Estimate for Akero Therapeutics’ 2023 loss per share has narrowed from $3.46 to $2.78. In the year so far, shares of Akero Therapeutics have fallen by 14.7%.

AKRO beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 7.96%.

In the past 90 days, the Zacks Consensus Estimate for Adaptimmune Therapeutics’ 2023 loss per share has narrowed from 78 cents to 46 cents. In the year so far, shares of Adaptimmune Therapeutics have fallen by 26%.

ADAP beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 36.89%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novartis AG (NVS) : Free Stock Analysis Report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report

Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research